Drug data last refreshed 4h ago · AI intelligence enriched 4h ago
CORTROPHIN-ZINC is a long-acting injectable corticotropin (ACTH) analog approved in 1955 for treating adrenocorticotropic hormone deficiency and related endocrine disorders. It functions as a natural pituitary hormone replacement, stimulating cortisol production in patients with adrenal insufficiency. The formulation uses zinc hydroxide as a depot mechanism to extend drug duration between doses.
Legacy product in terminal commercial phase with minimal growth opportunity; teams are typically small, lean, and focused on retention rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career roles on CORTROPHIN-ZINC are limited, specialized, and focused on legacy product management and market maintenance rather than growth or innovation. This is a holding/harvesting assignment suited to experienced professionals managing decline or those seeking stability in a niche therapeutic area.
Worked on CORTROPHIN-ZINC at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.